The treatment and management of an acute exacerbation of chronic obstructive pulmonary disease (COPD) first require that the diagnosis of the flare-up be firmly established. It makes it easier for the physician if the patient has already been diagnosed as a COPD case.
There are a host of treatment options and the list of medicines is mostly the same with varying doses for outpatient treatment, inpatient treatment, and for those admitted to the intensive care unit.
- Patients requiring outpatient treatment are managed with short-acting and/or long-acting bronchodilators, corticosteroids such as prednisolone, and antibiotics such as doxycycline (if infective).
- Hospitalized patients will require oxygen therapy as the first line of treatment in addition to the above.
- Those admitted to the ICU will, in addition, require noninvasive ventilation (NIV) or mechanical ventilation.
- Emergency treatment during an acute COPD exacerbation attack.
Effective treatment of a COPD exacerbation aims to relieve the acute symptoms, prevent further deterioration of lung function, and re-evaluation of the disease to reduce the risk of further flare-ups. The 8-week period after an initial exacerbation is a high-risk period for recurrence.
About 50% of exacerbations are not reported, which means that these flare-ups have mild symptoms. Those that are reported, are treated either on an outpatient basis or require hospitalization. In the hospital, the more severe cases may require treatment in the intensive care unit.
Indications for hospitalization
Moderate or level 2 cases require admission. The physician takes the call and will advise based on his clinical assessment.
Severe or level 3 cases will again require hospitalization. The criteria for hospital admission are that the patient is in respiratory distress or is at risk of it. Secondly, the presence of any comorbidity such as COPD complications makes a strong case for the hospital admission. Thirdly, the need for ventilator support may require admission to the intensive care unit.
The first step in the management of a COPD exacerbation is to keep the patient away from lung irritants such as dust, smoke, cooking aromas, and cigarette smoke including second-hand smoke. Reading the causes and risk factors that can lead to an exacerbation will be useful.
Goals of COPD flare-up treatment
- Treatment with medicines aims to make the patient’s breathing more comfortable and effortless.
- It also aims to reduce inflammation and infection due to bacteria and viruses in the lower airways.
- Thirdly, it aims at treating hypoxemia with oxygen therapy.
- Lastly, preventing further exacerbations is important in view of the fact that every exacerbation causes significant lung damage.
Mild cases can be treated on an outpatient basis. The moderate to severe exacerbations need hospitalization. The severity of an exacerbation is judged by the following tests:
- Pulse oximetry
- Arterial blood gases
- FEV1 results by spirometry
1. Outpatient management of mild COPD exacerbation
A mild or level 1 COPD exacerbation usually does not need admission and can be managed at home. Choices of drugs include:
Bronchodilators are drugs that open up the narrow and clogged airways. They form an essential part of treatment. The first step in outpatient management is to increase the dosage of inhaled short-acting bronchodilators, which the patient was already taking in his stable condition.
According to their mode of action, they are classified as short-acting and long-acting bronchodilators.
Pharmacologically, they are classified into anticholinergics, β2-agonists, and theophylline. The latter is rarely used due to its side effects. Bronchodilator therapy in COPD mainly rests with the former two drugs. The inhalable forms are typically used for quick relief. Inhalers or nebulizers can be used.
If the patient is already taking short-acting anticholinergic bronchodilators (e.g., ipratropium [Atrovent]) for his COPD treatment, its dose should be increased and, in addition, β2-agonists may be required to be added.
Inhaled short-acting β2-agonists are the preferred bronchodilators for both outpatient and inpatient management of exacerbations. Albuterol is preferred due to its lower cost and equal efficiency when compared with levalbuterol.
If the patient is already on a short-acting Beta agonist, (e.g., albuterol, levalbuterol [Xopenex]), increase its dose.
Research indicates that adding a long-acting anticholinergic to a β2-agonist (ipratropium and albuterol) works synergistically and improves the quality of life of COPD patients by relieving the dyspnea and increasing exercise tolerance as compared to using β2-agonists alone.
Recommended doses of inhaled bronchodilators:
- Albuterol 2.5 mg nebs four times a day or 2 puffs four times a day by metered inhaler with or without a spacer when stable
- and/or ipratropium 0.25-0.5mg inhaled three or four times daily as required.
Antibiotics are advised when the sputum is purulent indicated by its yellow or green color. This discoloration is a sign of infection in the airways. Mild exacerbations usually do not require antibiotics due to the absence of infection. In severe cases, antibiotic therapy becomes essential for infective exacerbations or when bronchodilators and steroids do not give relief. Antibiotics play a big role in avoiding treatment failure.
Narrow spectrum antibiotics are first given. If they do not work, broad-spectrum antibiotics are prescribed.
- Narrow spectrum antibiotics include amoxicillin, ampicillin, trimethoprim/sulfamethoxazole, and doxycycline.
- Broad spectrum antibiotics include a combination of amoxicillin/clavulanate, second- or third-generation cephalosporins, or quinolones
For outpatient patients or those admitted to the hospital, antibiotic selection if required is optimally made based on the results of gram stain sputum culture.
Commonly used antibiotics and their doses:
- Amoxicillin 500 mg orally three times a day
- Doxycycline 100mg orally twice daily
- Duration: 10 to 14 days
Oral corticosteroids are advised along with antibiotics and bronchodilators, especially in patients with purulent sputum. Steroids have a strong anti-inflammatory action and help to improve airflow inflammation and limitation.
Dosage: If FEV1 (through spirometry) is less than 50% predicted, use oral prednisone 30-40 mg/day for 7-10 days or budesonide through a nebulizer.
If you are coughing out a lot of mucus, which you are finding difficult to expectorate, your doctor may prescribe you a drug called a mucolytic. It comes in a tablet or liquid form and makes the mucus thin and easy to cough out.
2. Hospital management of COPD exacerbation
Patients admitted to a hospital for a COPD exacerbation are the more severe cases and need a more aggressive approach to treatment. Inpatient mortality of patients with COPD exacerbations is 3 to 4 percent. Patients admitted to the Intensive care unit have a 43 to 46 percent risk of death within the first year after hospitalization.
The indications for hospital admission are:
- Development of respiratory acidosis as indicated by its initial symptoms such as a headache, anxiety, blurred vision, restlessness, and confusion
- Presence of complications and comorbidities
- Need for ventilator support
If the patient has been advised hospitalization, he is likely to have a moderate or serious exacerbation and will require oxygen therapy.
Patients with saturation PaO2 less than 60 mm Hg can be given oxygen through a nasal cannula or oxygen face mask. This will take care of the hypoxemia and reduce the mortality risk.
- Administer oxygen at 2 to 4 liters per minute through a nasal cannula;
- Maintain oxygen of more than 91% measured by the pulse oximeter. If needed increase oxygen dose.
- If PCO2 is more than 45, give oxygen through a Venturi mask.
Higher O2 administration increases the risk of respiratory failure. Therefore, close monitoring is essential.
Start patient on inhaled anticholinergic bronchodilators such as Ipratropium. Increase dose if necessary.
If there is no relief even after increasing the dose of the Ipratropium, add β2-agonist to anticholinergic bronchodilators. If required, the dose of β2-agonist, too, can be increased for better relief. They improve dyspnea and increase exercise tolerance.
Aminophylline/theophylline should be avoided due to serious side effects.
Broad spectrum antibiotics are used if there is no relief from narrow spectrum antibiotics. The use of antibiotics kills the infection and decreases the risk of treatment failure and mortality.
Admitted patients are those with severe exacerbations. Stronger antibiotics become necessary. Usually, the following fourth-generation synthetic fluoroquinolone antibacterials are preferred.
- Moxifloxacin: dose 400mg once daily for 5 days
- Levofloxacin: dose 500mg or 750mg PO once daily for 7 days
Maintenance therapy with Azithromycin significantly decreases the frequency of the exacerbations. The higher strength of this antibiotic given over a shorter period of time has advantages and should, therefore, be considered for use in COPD patients who have frequent exacerbations.
Though considered quite safe, the only drawback is its side effect of causing malignant arrhythmia, which can cause sudden cardiac death.
However, the risk of cardiovascular death associated with azithromycin long-term prophylactic therapy in COPD patients is reported to be 1 in 20,000.
Corticosteroids are necessarily given to hospitalized patients. Oral tablets can be used. If the patient is unable to tolerate them due to reasons such as GERD, intravenous steroids can be given.
The use of steroids decreases the risk of further exacerbations, treatment failures, and length of hospital stay. It also improves breathing, FEV1, and hypoxemia. Long-term steroid therapy, when given, has to be stopped by gradually tapering the doses.
Methylprednisolone 125mg IV 6 hourly for 3 days then reduce the dose as follows:
- Oral prednisone 60mg daily for 4 to 7 days,
- followed by 40mg daily for 8 to 11 days and finally,
- 20mg daily for 12 to 15 days
3. COPD exacerbation management in ICU
If the patient exhibits symptoms of respiratory acidosis, he needs admission to the intensive care unit with 24-hour monitoring of his vital signs.
In addition to the treatment given in the hospital rooms, he will require respiratory assistance with noninvasive positive pressure ventilation (NIPPV), simply called non-invasive ventilation (NIV). If the desired blood gas levels are not achieved with NIV, he will require mechanical ventilation –- meaning he will be intubated with an endotracheal tube and put on a ventilator.
Noninvasive Positive Pressure Ventilation (NIPPV)
NIPPV is indicated in the management of COPD exacerbation when the patient has worsening respiratory acidosis and persisting hypoxemia when oxygen therapy via nasal cannula or high-flow oxygen mask becomes inadequate.
NIPPV improves respiratory acidosis, normalizes respiratory rate, improves breathlessness, avoids the need for intubation, and reduces mortality, and length of hospital stay.
Mechanical ventilation is indicated when:
- The patient cannot tolerate NIPPV
- Continues to have a progressively worsening hypoxemia, respiratory acidosis, altered mental state, and hypercapnia despite NIPPV
- Has comorbid conditions such as a heart attack or sepsis.
4. COPD exacerbation emergency treatment
Treatment options provided in the Emergency Department include:
Oxygen is the first line of treatment that is administered to the patient of a COPD exacerbation during an emergency that can ease the symptoms. It will help raise the oxygen blood levels, which should be checked by doing the arterial blood gas (ABG) test. The results will also help with the proper titration dose of the oxygen. Venturi masks are better to control the oxygen flow than nasal prongs
A systemic steroid, preferably I.V. prednisolone, is started and given for the first three days followed by oral tablets gradually reducing the doses over the next days.
Antibiotics, preferably Moxifloxacin or Levofloxacin by intravenous route will help fight the infection on an SOS basis
Short-acting bronchodilators are used during an emergency for rapid relief. Start patient on inhaled anticholinergic bronchodilators such as Ipratropium. Add β2-agonist such as Albuterol to the anticholinergic bronchodilators. Doses can be increased as required.
Once the emergency department has treated the patient’s symptoms, the doctor will decide if the patient is to be discharged with orders or needs admission.
When does a patient qualify for discharge?
A patient with COPD exacerbation admitted to a hospital for treatment, qualifies for discharge when he fulfills the following conditions:
- He has stable clinical symptoms
- His vital signs are normal
- His arterial partial pressure of oxygen is more than 60 mm Hg for at least 12 hours
- He does not require a short-acting bronchodilator (eg. Albuterol) more often than every four hours.
Advice on discharge
Once his treatment for COPD exacerbation is over indicated by the stabilization of his symptoms, the COPD patient is given the following advice on discharge from the hospital
- Smoking cessation
- Avoid all types of lung irritants
- Immunization against influenza every year and pneumonia once only
- Pulmonary rehabilitation program to reduce risk of further exacerbation
- Long-term oxygen therapy
- Regular use of inhaled bronchodilators
- Inhaled corticosteroids as and when necessary
- Patients who are non-ambulatory should receive prophylactic deep venous thrombosis treatment.